Innocan Pharma Corporation Sets Sights on NYSE American Listing and Concurrent Offering

Innocan Pharma Corporation Sets Sights on NYSE American Listing

January 2, 2026—HERZLIA, Israel and CALGARY, AB
Innocan Pharma Corporation (CSE: INNO) has made an exciting announcement regarding its plans to list on the NYSE American around January 7, 2026. This major step is contingent upon the approval of its listing application and compliance with all requisite exchange rules.

Innocan, known for its innovative drug delivery platforms, is also planning a concurrent offering of its securities, pending market conditions and necessary regulatory approvals. Further details about this offering will be provided through formal filings with the Securities and Exchange Commission (SEC) and SEDAR+.

Innocan's common shares will continue trading on OTC Markets' OTCQB until the close of trading on January 6, 2026. After the listing becomes effective on NYSE American, trading on the OTCQB will cease. Existing stockholders of Innocan are not required to take any action for the transition to the NYSE American, as shares will also continue to trade on the Canadian Securities Exchange under the symbol "INNO".

About Innocan Pharma Corporation

Innocan operates at the forefront of the pharmaceuticals and wellness sectors. With its groundbreaking CBD-loaded liposome drug delivery technology, the company aims to provide a precise dosage and sustained, controlled release of synthetic CBD, specifically for non-opioid pain management. Moreover, Innocan is dedicated to advancing health and wellness through a diverse range of high-performance self-care and beauty products, marketed through its majority-owned subsidiary, BI Sky Global Ltd., which specializes in targeted online sales.

While Innocan's upcoming listing on the NYSE American signals a significant milestone for the company, it is crucial to note that this announcement does not serve as an offer or solicitation to purchase or sell any securities. The intention behind this communication is purely informational and based on forward-looking statements about potential advancements in regulatory approvals, market entry, and product distribution timelines.

Market Outlook

The pharmaceutical sector is witnessing swift advancements, particularly in drug delivery technologies. Innocan's emphasis on developing cutting-edge platforms positions the company uniquely in an ever-evolving market. However, investors should remain aware of various risks that may affect Innocan's anticipated timeline for market entry, which can be influenced by external factors such as economic conditions, governmental regulations, and supply chain dynamics.

In conclusion, Innocan Pharma Corporation is poised for a transformative year with its anticipated listing and concurrent offering, reflecting the company’s ongoing commitment to innovation in the pharmaceutical landscape. As it embarks on this new chapter, stakeholders eagerly await how the company’s strategies will unfold and how they will impact the broader wellness and pharmaceuticals industry.

For further inquiries, contact:
Iris Bincovich, CEO
Phone: +1-516-210-4025
Email: [email protected]
For more information, visit Innocan Pharma's Website.